Effects of Kangaroo Care on Circadian Rhythm, Growth and Physiological Effects
Launched by SIBEL KÜÇÜKOĞLU · Sep 5, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how regular kangaroo care—where a parent holds their premature baby skin-to-skin—affects the baby's growth, sleep patterns, and overall health in the neonatal intensive care unit (NICU). The researchers want to see if this type of care can help improve the baby's body clock, growth rates, and even the levels of cortisol (a stress hormone) in breast milk.
To participate in this study, babies need to be born between 28 to 37 weeks of pregnancy and weigh more than 1000 grams (about 2.2 pounds) at birth. They should also have a good APGAR score, which is a quick test done after birth to check how well the baby is doing. However, babies who need machines to help them breathe, have certain medical conditions, or are on specific medications that affect sleep won't be eligible. If families decide to participate, they can expect to engage in regular kangaroo care sessions, and the study will track how this impacts their baby's development and health over time.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being between 28+0-37 weeks of pregnancy,
- • Birth weight \>1000 g,
- • APGAR score \>7 at the 5th minute after birth,
- • Ability to feed every 2-3 hours
- Exclusion Criteria:
- • Getting mechanical ventilation support
- • Undergoing surgery
- • Having diseases and disorders such as congenital brain malformations, meningitis, seizures, encephalopathy, congenital abnormalities, history of intraventricular bleeding, herpes, sepsis and heart or metabolic diseases.
- • Taking medication that affects sleep patterns, such as theophylline, phenobarbital, midazolam, caffeine, fentalnil
- • Having developed intraventricular hemorrhage
About Sibel Küçükoğlu
Sibel Küçükoğlu is an esteemed clinical trial sponsor with a commitment to advancing medical research and innovation. With a focus on enhancing patient outcomes through rigorous clinical studies, Sibel Küçükoğlu collaborates with leading healthcare professionals and institutions to ensure the highest standards of trial design, execution, and compliance. The organization is dedicated to fostering a transparent and ethical research environment, prioritizing participant safety and data integrity while striving to bring novel therapeutic solutions to market. Through strategic partnerships and a patient-centered approach, Sibel Küçükoğlu aims to contribute significantly to the field of clinical research and improve healthcare practices globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Konya, Selcuklu, Turkey
Patients applied
Trial Officials
Sibel Kucukoglu, Prof
Study Director
Selcuk University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported